sarclisa
sanofi winthrop industrie - isatuximab - multippelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
baraclude 0.5 mg
abacus medicine a/s - entekavirmonohydrat - tablett, filmdrasjert - 0.5 mg
baraclude 1 mg
abacus medicine a/s - entekavirmonohydrat - tablett, filmdrasjert - 1 mg
aclasta 5 mg
2care4 aps - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg
janumet 50 mg / 1000 mg
paranova as (1) - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg
janumet 50 mg / 1000 mg
2care4 aps - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg
janumet 50 mg / 850 mg
2care4 aps - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg
blincyto 38.5 mikrog
orifarm as - blinatumomab - pulver til konsentrat og oppløsning til infusjonsvæske, oppløsning - 38.5 mikrog
invanz 1 g
2care4 aps - ertapenem - pulver til konsentrat til infusjonsvæske, oppløsning - 1 g
kisplyx 4 mg
orifarm as - lenvatinibmesilat - kapsel, hard - 4 mg